ANGELALIGN announced its interim results, with profit attributable to owners of the company at USD 14.643 million, a year-on-year increase of 362.65%

According to the Zhitong Finance APP, ANGELALIGN (06699) announced its mid-term results for 2025, with revenue of $161.4 million, an increase of 33.1% year-on-year. Gross profit was approximately $100 million, an increase of 32.9% year-on-year. Adjusted net profit was $19.5 million, an increase of 84.8% year-on-year. The profit attributable to the company's owners was $14.643 million, a year-on-year increase of 362.65%; earnings per share were $0.09, with a special interim dividend of HKD 0.46 per share.

In the first half of 2025, the company achieved a robust performance. The number of cases reached new heights, and the efficient operation of the medical design center and the invisible aligner production base jointly drove revenue, gross profit, and operating profit growth year-on-year. The company's profit performance during the reporting period also benefited from strict cost control measures taken in response to an anticipated more severe tariff environment, including: postponing recruitment in several areas such as sales, marketing, clinical support, and customer service, as well as delaying the operation of medical design centers and production bases outside mainland China. During the reporting period, the number of cases in global markets outside mainland China (including AngelAligner brand aligners, Aditek brand aligners, and aligners customized for important strategic clients' simple cases) grew rapidly, reflecting the group's initial success in entering new markets and benefiting from low-hanging fruit.

The company expanded its market coverage outside mainland China through high-quality medical design support, stable delivery, continuous education and training led by key opinion leaders (KOLs), and aligners customized for important strategic clients' simple cases. During the reporting period, the company achieved approximately 117,200 invisible aligner cases in global markets outside mainland China (including AngelAligner brand aligners, Aditek brand aligners, and aligners customized for important strategic clients' simple cases), representing a year-on-year increase of 103.5%. This reflects both the low business base from last year and the company's initial success in entering previously uncharted new markets and benefiting from low-hanging fruit. Looking ahead, the company expects to increase investment in sales, marketing, clinical support, and customer service to establish a more solid and sustainable influence